Guidance

Update on HIV, Cardiovascular Risk and Statin use

Summary

People living with HIV (PLWH) are at higher risk of atherosclerotic cardiovascular disease. Q-risk 3 does not adjust for HIV. A recent study has shown that there is a significant reduction of major adverse cardiovascular events in participants assigned to a statin.

 

Recommendations

All 40 yr + PLWH offered a statin.

Patients with a Q-risk 5%+ should be prioritised

Atorvastain 20mg first choice at present

If unable to tolerate to try other alternative lipid lowering agent

 

Action

In HIV clinic we are discussing CVD, Q-Risk and statin use with all patients 40 years+

We will communicate the Q-risk score and request consideration from yourselves regarding statin prescription and monitoring in all PLWH 40yrs + with a Q-risk 5%+.

We will ask the PLWH who wish to consider a statin to approach you to discuss this further.

First Published
26 July 2024
Updated On
7 July 2025
Due to be Reviewed
26 July 2025
Not signed in.

Please Login or Register an account to access the ability to favourite this.
Share this article

You might also find this useful...

Expansion of Shingles Vaccination
Expansion of Shingles Vaccination
31 July 2025
A letter has been published detailing the planned expansion of the Shingles vaccination programme to include all those who are severely immunosuppressed and aged 18-49 years old from 1 September…
Cont. Reading
OpenSAFELY Expansion – Action Required
OpenSAFELY Expansion – Action Required
30 July 2025
The Data Provision Notice (DPN) for OpenSAFELY now permits expansion beyond COVID-19-related analyses. The opt-in functionality for EMIS was rolled out this week.  SystmOne already has this functionality in place.…
Cont. Reading